- Previous Close
19.11 - Open
19.32 - Bid 19.47 x 800
- Ask --
- Day's Range
19.27 - 19.58 - 52 Week Range
16.66 - 22.76 - Volume
329,119 - Avg. Volume
288,746 - Market Cap (intraday)
11.467B - Beta (5Y Monthly) 0.86
- PE Ratio (TTM)
19.94 - EPS (TTM)
0.98 - Earnings Date Nov 5, 2024
- Forward Dividend & Yield 0.64 (3.29%)
- Ex-Dividend Date May 17, 2024
- 1y Target Est
20.08
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. It also develops, manufactures, and distributes various health care products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, systems for water treatment, and acute cardiopulmonary and apheresis products. In addition, the company develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. Fresenius Medical Care AG was incorporated in 1996 and is headquartered in Bad Homburg, Germany.
www.freseniusmedicalcare.com113,639
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: FMS
View More
Performance Overview: FMS
Trailing total returns as of 11/1/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: FMS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: FMS
View MoreValuation Measures
Market Cap
11.47B
Enterprise Value
23.05B
Trailing P/E
19.95
Forward P/E
10.39
PEG Ratio (5yr expected)
0.40
Price/Sales (ttm)
0.55
Price/Book (mrq)
0.76
Enterprise Value/Revenue
1.09
Enterprise Value/EBITDA
6.46
Financial Highlights
Profitability and Income Statement
Profit Margin
2.73%
Return on Assets (ttm)
2.90%
Return on Equity (ttm)
5.06%
Revenue (ttm)
19.42B
Net Income Avi to Common (ttm)
530.26M
Diluted EPS (ttm)
0.98
Balance Sheet and Cash Flow
Total Cash (mrq)
1.09B
Total Debt/Equity (mrq)
77.56%
Levered Free Cash Flow (ttm)
1.13B
Research Analysis: FMS
View MoreCompany Insights: FMS
FMS does not have Company Insights
Research Reports: FMS
View MoreFresenius Medical Care Earnings: Outlook Merely Maintained as Mortality Concerns Reemerge
Fresenius Medical Care is the largest dialysis company in the world, treating over 300,000 patients from roughly 3,750 clinics across the globe as of mid-2024. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market and benefits from being the world's only fully integrated dialysis business. Services account for roughly 80% of firmwide revenue, including care coordination and ancillary operations, while products account for the other roughly 20%.
RatingPrice TargetFresenius Medical Care Earnings: Outlook Merely Maintained as Mortality Concerns Reemerge
Fresenius Medical Care is the largest dialysis company in the world, treating over 300,000 patients from roughly 3,750 clinics across the globe as of mid-2024. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market and benefits from being the world's only fully integrated dialysis business. Services account for roughly 80% of firmwide revenue, including care coordination and ancillary operations, while products account for the other roughly 20%.
RatingPrice TargetFresenius Medical Care Earnings: Outlook Merely Maintained as Mortality Concerns Reemerge
Fresenius Medical Care is the largest dialysis company in the world, treating over 300,000 patients from roughly 3,750 clinics across the globe as of mid-2024. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market and benefits from being the world's only fully integrated dialysis business. Services account for roughly 80% of firmwide revenue, including care coordination and ancillary operations, while products account for the other roughly 20%.
RatingPrice TargetFresenius Medical Care Earnings: Strong Start to 2024 but No Change to Outlook or Fair Value Yet
Fresenius Medical Care is the largest dialysis company in the world, treating about 345,000 patients from over 4,100 clinics across the globe as of December 2022. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market and benefits from being the world's only fully integrated dialysis business. Services account for roughly 80% of firmwide revenue, including care coordination and ancillary operations, while products account for the other roughly 20%. Products typically enjoy a higher margin, making them a strong contributor to the bottom line.
RatingPrice Target